Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the disease. Adherence to prescribed therapy has an impact on clinical outcomes. Reducing the pill/tablet count …

  • 100 views
  • 26 Mar, 2021
  • 214 locations
First in Human Study of the DaVingi TR System in the Treatment of Patients With Functional Tricuspid Regurgitation

The DaVingi System is a percutaneous trans-catheter device delivered using right heart catheterization through the right internal jugular vein. The DaVingi System is designed for performing ring

  • 8 views
  • 04 Feb, 2021
  • 6 locations
Treatment With the Ketone Body 3-hydroxybutyrate in Patients With Cardiogenic Shock

hemodynamic effect of enteral ketone ester versus placebo in 12 patients with cardiogenic shock Methods Right heart catheterization will be installed to monitor cardiac pressures and output. The

  • 0 views
  • 27 Jan, 2021
  • 1 location
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects.

heart disease
forced expiratory volume
treprostinil
hemodynamic evaluation
connective tissue disease
  • 1 views
  • 26 Jan, 2021
  • 3 locations
Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction

The global objective of this study is to determine the mechanisms of exercise intolerance and dyspnea on exertion (DOE) in patients with HFpEF and based on this pathophysiology, test whether specific exercise training programs (whole body vs single leg) will result in improved exercise tolerance.

heart failure with preserved ejection fraction
diastolic dysfunction
ejection fraction
dyspnea
  • 0 views
  • 25 Jan, 2021
  • 1 location
SIRONA 2 Trial Heart Failure NYHA Class III

This is a prospective, multi-center, open-label, single-arm CE-Mark trial to assess device safety and efficacy of the Cordella PA Sensor System in 60 New York Heart Association (NYHA) Class III Heart Failure patients who will receive the Cordella PA Sensor Implant.

  • 47 views
  • 10 Feb, 2021
  • 10 locations
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)

The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.

  • 0 views
  • 11 Apr, 2021
  • 2 locations
Phase 2 Study to Assess Safety Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH

This is a multi-center, randomized, double-blind, controlled, Phase 2 study to assess the safety, tolerability, and efficacy of pemziviptadil (PB1046) at the optimally titrated dose after 16 weeks of treatment. Subjects will be randomized in a 2:1 ratio to one of two parallel dose groups: a) high-dose group where PB1046 …

heart disease
left ventricular end-diastolic pressure
forced expiratory volume
body mass index
hypertension
  • 29 views
  • 14 Apr, 2021
  • 26 locations
Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)

Splanchnic vasoconstriction may contribute to decompensation of chronic heart failure (HF) via volume redistribution from the splanchnic vascular bed to the central compartment. This is a sympathetically mediated reflex and can be interrupted through a splanchnic nerve block (SNB). We hypothesize that interruption of the efferent/afferent innervation of the splanchnic …

  • 0 views
  • 26 Jan, 2021
  • 1 location
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

Pulmonary Arterial Hypertension or PAH is a progressive condition for which there is no cure. Even with substantial pharmacologic advances in the modern treatment era, survival still remains unacceptably poor, as reported in large PAH registries. Preclinical studies suggest that the administration of allogeneic CDCs have the potential to reduce …

  • 96 views
  • 25 Mar, 2021
  • 1 location